12 results about "Metabolic change" patented technology

The application discloses a method for screening garlic fructan adversity response key enzyme genes and metabolites based on transcriptome and metabolome, and the method can better analyze the relationship between genes and metabolites by jointly analyzing the fructan-related differentially expressed genes measured by the transcriptome and the fructan-related metabolism substances with obvious metabolism changes measured by the metabolome, and constructing a gene-metabolite network interaction diagram.

The invention discloses application of a fucoidin degradation product Fuc-S in a pharmaceutical composition for preventing, relieving or treating type 2 diabetes mellitus and liver injury, and relates to the technical field of biological medicines. The invention provides a new effect of fucoidin Fuc-S in treating diabetic liver injury, and particularly, the fucoidin Fuc-S can significantly improve blood glucose control (reducing fasting blood glucose and enhancing sugar tolerance) and blood lipid spectrum (reducing TG, TC and LDL-C and increasing HDL-C) of diabetic mice, alleviate liver fatty degeneration and reduce serum ALT / AST level, and shows a significant liver protection effect. Furthermore, the Fuc-S can be used for remodeling the intestinal flora structure through specific enrichment of beneficial bacteria such as Bacteroides acdifaciens and the like, so that the generation of short-chain fatty acid (SCFAs) with a liver protection effect is promoted. The flora and metabolic change jointly improve the oxidative stress state of the liver, inhibit pro-inflammatory response and reduce lipid accumulation. The invention provides a novel nutrition intervention strategy for prevention and treatment of T2DM and liver complications thereof.

This invention relates to the field of multi-organ dysfunction (MOD) early warning technology, specifically to an MOD early warning method for patients with severe burns. The method includes the following steps: acquiring heart rate, mean arterial pressure, respiratory rate, blood oxygen saturation, lactate concentration, and urine output per unit time; calculating the rate of lactate change at adjacent time points to form a sequence; comparing the rate of change across time intervals to obtain the difference in change; combining heart rate and blood oxygen saturation to calculate circulatory load; and counting the number of early warning triggers that meet risk conditions. In this invention, by calculating the rate of change of lactate concentration at adjacent time points and combining it with interval direction statistics, tissue metabolic changes show trend characteristics; the rate of change of urine output combined with mean arterial pressure forms a record of renal perfusion changes, providing a continuous characterization of perfusion status; heart rate and blood oxygen saturation are used to calculate circulatory load; multiple physiological signals are linked for judgment; and recurring abnormalities are expressed through the number of triggers. This improves the stability and predictability of MOD risk identification in critically burned patients.

The application relates to application of phosphatidylinositol and phosphatidylglycerol as metabolic markers for predicting intracranial atherosclerosis progression, and belongs to the technical field of medical biological detection. In the scheme, single-sample MR analysis is carried out by combining RICAS cohort data with external database data, causal correlation between metabolites and ICAS is analyzed, and serum biomarkers phosphatidylinositol PI 18:0 / 22:6 and phosphatidylglycerol PG 18:1 / 18:2 for ICAS occurrence and development are screened out by combining characteristic metabolic changes of ICAS with causal correlation analysis. ICAS progression is collected through prospective follow-up of the RICAS cohort, the correlation between the serum biomarkers and the ICAS progression is established, and it is verified that the serum biomarkers have transformation application value and can be used as a new biomarker for early prediction of ICAS progression and derivation.

A method for treating low-level blast traumatic brain injury includes administering a phosphodiesterase-5 (PDE5) inhibitor, such as sildenafil, to a subject following exposure of the subject to one or more low-level blasts. Administration of the PDE5 inhibitor may prove useful with respect to improving the vascular integrity of a subject by increasing brain capillary respiration, mitochondrial respiration, mitochondrial density, mitochondrial biogenesis, astrocyte level or homeostasis, and / or tight junction protein expression in the brain of the subject and / or inducing positive metabolic change in the subject by increasing NAD+ / NADH metabolism. Methods for mitigating the effects of blast injury on the vascular integrity of a subject and inducing metabolic change are also provided.

The application belongs to the technical field of biological analysis and detection, and discloses a method for extracting, measuring and mass spectrum imaging visualizing high-order characteristic information of spatial metabolome. Specifically, the application relates to a mass spectrum imaging analysis method for evaluating the in-vivo active action site and action intensity of a preclinical candidate drug, which can be applied to the prediction of potential action sites, molecular targets and molecular mechanisms of a drug. The index "metabolic disturbance score" introduced in the application can be used to measure the change of high-order characteristics of spatial metabolome, and the metabolic changes of different spatial sites can be visually represented in images, so that the overall metabolic state change of each part of the body under the action of the candidate drug can be objectively evaluated. In addition, the application can be used to evaluate the influence of the drug on specific metabolic pathways, species, functions or biological transformation types, which is helpful to explain the potential molecular mechanism of the drug action and accelerate the discovery of new drug targets and clinical indications in the pharmaceutical industry.

The invention relates to application of phosphatidylinositol and phosphatidylglycerol as metabolic markers for predicting the progress of intracranial atherosclerosis, and belongs to the technical field of medical biological detection. According to the scheme, RICAS queue data and external database data are combined for single-sample MR analysis, the causal association between metabolites and ICAS is analyzed, ICAS characteristic metabolic change and causal association analysis are combined, serum biomarkers of phosphatidylinositol PI 18: 0 / 22: 6 and phosphatidylglycerol PG 18: 1 / 18: 2 of ICAS occurrence and development are screened out, ICAS progress is collected through prospective follow-up visit of an RICAS queue, and the ICAS development rate is improved. The association between the gene and ICAS progress is established, and the gene has a transformation application value and can be used as a novel biomarker for early prediction of ICAS progress and development.

The invention discloses application of a microbiota-metabolite combined marker in screening gastric cancer biomarkers, and belongs to the technical field of biology. According to the application of the microbiota-metabolite combined marker in screening of gastric cancer biomarkers, GM and metabonomics data are integrated, and microbe and metabolic changes in specific stages along the CS are described. Atrophy represents a key inflection point of transition from in vivo equilibrium to carcinogenesis, and erosion is a transition state. The microbiota-metabolite combined marker is expected to be used for mechanism insight of non-invasive early detection, disease stratification and GC metabolism dependence.

Autophagy is typically activated by starvation, allowing cells and organisms to mobilize their energy reserves. It is known that pharmacological modulation of autophagy represents a therapeutic potential. Here the inventors report that a protein that is released from cells in an unconventional, autophagy-dependent manner, namely, diazepam binding inhibitor (DBI), regulates autophagy. In particular, the inventors demonstrate that DBI inhibits autophagy and that the supply of recombinant DBI to mice enhanced glycolysis, enhanced lipogenesis, and inhibited fatty acid oxidation. The inventors show that neutralisation of DBI by a monoclonal antibody and an active immunization by means of an immunogenic DBI derivative eliciting autoantibodies induce autophagy and lead to metabolic changes that increase starvation-induced weight loss, reduce food intake upon refeeding, and reduce weight gain in response to hypercaloric diets. Accordingly, the present invention relates to methods and pharmaceutical compositions for modulating autophagy based on the modulation of the activity or expression of DBI.

The invention relates to the technical field of medication management, and discloses a tumor patient medication safety intelligent management system, which comprises a data acquisition and integration module, an intelligent analysis and decision module, a medication process management module, a monitoring and feedback module and an optimization module, by constructing an integrated framework of'multi-source data fusion-intelligent analysis and decision-dynamic accurate management ', clinical data of patients, drug attribute data and dynamic drug interaction data are fused, and a machine learning algorithm is applied to establish a personalized drug metabolism kinetic model; the method realizes the crossing from universal medication management to personalized and dynamic management, can accurately predict the metabolic change of the drug in the body of the patient, dynamically evaluates the drug interaction risk in combination with the real-time physiological state, avoids the potential medication safety problem in advance, standardizes the whole medication process through the knowledge graph, reduces the manual operation error, and improves the medication safety. And the accuracy and normalization of medication safety management of tumor patients are greatly improved.

The invention belongs to the technical field of traditional Chinese medicine quality control and analysis, and particularly discloses a method for screening paris polyphylla quality markers. According to the method, a blood stasis syndrome animal model is constructed, a biological sample of the blood stasis syndrome animal model is collected, an endogenous biomarker set is generated in combination with metabonomics analysis, meanwhile, quantitative analysis is conducted on the callback degree after drug intervention, and the relevance between pharmacodynamic substances and metabolic changes is revealed. In-vitro chemical analysis is carried out on paris polyphylla related materials to obtain chemical component spectrum data, and blood entering component data is extracted in combination with serum drug chemical analysis, so that accurate positioning of potential drug effect substances is realized. Finally, the paris polyphylla quality marker is screened out through traceability comparison and a comprehensive evaluation system, and a scientific basis is provided for quality control of traditional Chinese medicine. The accuracy of the screening result is improved, the repeatability and reliability of the screening process are guaranteed, and the misjudgment risk caused by data deviation is reduced.

The invention provides an sTBI prognosis prediction method and device and electronic equipment, and relates to the technical field of crossing of medical information technologies and clinical neurosciences. Biomarker data, multi-omics data and corresponding brain imaging data of multiple periods from an acute period to a recovery period after brain injury of a patient are obtained; and the dynamic change of molecules and images in the pathological process is comprehensively captured. Multiple omics expression trends are associated through biomarkers, brain injury prognosis core key molecules are accurately positioned, and false positive interference of a traditional method is avoided. The change of the anatomical structure of the brain injury is combined with the change of functional metabolism, so that the pathophysiological state of the brain injury is comprehensively reflected. On the premise, time sequence correlation is carried out on the multi-dimensional data, and a new strategy is provided for improving the sTBI clinical curative effect by revealing the dynamic evolution rule of the brain injury data and constructing a precise intervention system.